On September 30, 2021 VECT-HORUS reported to be part of the research in PDAC with its theranostic agents to first improve PDAC diagnosis, response monitoring or recurrence detection in operated patients and also treat them (Press release, Vect-Horus, SEP 30, 2021, View Source [SID1234590620]).
Cedric malicet, Oncology Department Manager, is pleased to inform you of the recent publication of the article " LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma " in Communications Biology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!